Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Day One Biopharmaceuticals (DAWN) Non Operating Income: 2022-2024

Historic Non Operating Income for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to $128.9 million.

  • Day One Biopharmaceuticals' Non Operating Income fell 30.59% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.3 million, marking a year-over-year decrease of 84.09%. This contributed to the annual value of $128.9 million for FY2024, which is 651.84% up from last year.
  • Day One Biopharmaceuticals' Non Operating Income amounted to $128.9 million in FY2024, which was up 651.84% from $17.1 million recorded in FY2023.
  • In the past 5 years, Day One Biopharmaceuticals' Non Operating Income ranged from a high of $128.9 million in FY2024 and a low of $4.7 million during FY2022.
  • In the last 3 years, Day One Biopharmaceuticals' Non Operating Income had a median value of $17.1 million in 2023 and averaged $50.3 million.
  • Data for Day One Biopharmaceuticals' Non Operating Income shows a peak YoY skyrocketed of 651.84% (in 2024) over the last 5 years.
  • Day One Biopharmaceuticals' Non Operating Income (Yearly) stood at $4.7 million in 2022, then surged by 262.67% to $17.1 million in 2023, then surged by 651.84% to $128.9 million in 2024.